2Field-Smith A,Morgan GJ,Davies FE. Bortezomib (Velcadetrade mark) in the Treatment of Multiple Myeloma[J].Ther Clin Risk Manag,2006, 2(3) :271-279.
3Oakervee HE,Popat R,Curry N,et al. PAD combination therapy (PS-341/ bortezomib,doxorubicin and dexamethasone)for previously untreated patients with multiple myeloma[J]. Br J Haematol,2005,129(6) :755-762.
4Badros A,goloubeva O,Dalal JS,et al. Neurotoxicity of bortezomib therapy in multiple myeloma:a single-center experience and review of the literature[J]. Cancer,2007,110(5) : 1042-1049.
5Chauhan D,Hideshima T,Mitsiades C,et al. Proteasome inhibitor therapy in multiple myeloma[J]. Mol Cancer Ther, 2005,4(4):686-692.
6Briehardson PG,Barlogie BB,Berenson NJ,et al. A phase 2 study of bortezomib in relapsed,refractory myeloma [J]. N Engl J Med,2003,348 (26) : 2609-2617.
7Colson K,Doss DS,Swift R,et al.Expanding role of bortezomib in multiple myeloma : nursing implications [J]. Cancer Nurs, 2008,31 (3) : 239- 249.
8Barlogie B,Shaughnessy J,Tricot G,et al. Treatment of multiple myeloma[J]. Blood,2004,103:20-32.
9Bross PF,Kane R,Farrell AT,et al.Approval summary for borte-zomib for injection in the treatment of multiple myeloma[J]. Clin CaneerRes,2004, 10: 3954-3964.
10VOORHEES PM.DEES EC.O'NEIL B,et al.The proteasome as a target for cancer therapy[J].Clin Cancer Res,2003,9(17):6316-6325
2Richardson PG,Barlogie B,Berenson J,et al.A phase 2 study of bortezomib in relapsed/refractory myeloma.N Engl J Med,2003,348:2609-2617.
3Jagannath S,Durie BG,Wolf J,et al.Bortezomib ther- apy alone and in combination with dexamethason for previously untreated symptomatic multiple myeloma.Br J Haematol,2005,129(7):776-783.
4Moreau P,Pylypenko H.Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma:a randomised,phase 3,non-inferiority study.Lancet Oncol,2011:431-440.
